447 related articles for article (PubMed ID: 15468193)
1. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
Breckpot K; Heirman C; Neyns B; Thielemans K
J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193
[TBL] [Abstract][Full Text] [Related]
2. DNA and RNA modified dendritic cell vaccines.
Morse MA; Lyerly HK
World J Surg; 2002 Jul; 26(7):819-25. PubMed ID: 11948364
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered dendritic cell-based cancer vaccines (review).
Bubeník J
Int J Oncol; 2001 Mar; 18(3):475-8. PubMed ID: 11179474
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccines for cancer treatment.
Gabrilovich DI
Curr Opin Mol Ther; 2002 Oct; 4(5):452-8. PubMed ID: 12435046
[TBL] [Abstract][Full Text] [Related]
6. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
7. Viral vectors for gene transfer into antigen presenting cells.
Monahan SJ; Salgaller ML
Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662
[TBL] [Abstract][Full Text] [Related]
8. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
[TBL] [Abstract][Full Text] [Related]
9. Priming anticancer active specific immunotherapy with dendritic cells.
Mocellin S
Curr Opin Investig Drugs; 2005 Jun; 6(6):576-81. PubMed ID: 15988908
[TBL] [Abstract][Full Text] [Related]
10. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.
Gulen D; Abe F; Maas S; Reed E; Cowan K; Pirruccello S; Wisecarver J; Warkentin P; Northam M; Turken O; Coskun U; Senesac J; Talmadge JE
Int Immunopharmacol; 2008 Dec; 8(13-14):1728-36. PubMed ID: 18793758
[TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells as vectors for immunotherapy of cancer.
Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
[TBL] [Abstract][Full Text] [Related]
14. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
15. Poxviruses as vectors for cancer immunotherapy.
Kwak H; Hörig H; Kaufman HL
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
[TBL] [Abstract][Full Text] [Related]
16. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
17. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based immunotherapy.
Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
20. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
Dullaers M; Thielemans K
J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]